Of These 3 Battleground Biotech Stocks, 1 Is a Buy

The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable.

First up:

Amarin has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much traction. The hope was that the company could get FDA approval for a wider population of patients with moderately high triglyceride levels, but the FDA shot down the idea.

Prosensa is developing a Duchenne muscular dystrophy drug called drisapersen. The drug failed a phase 3 trial, but the company thinks it might still be able to get the drug approved.

Jazz Pharmaceuticals is a specialty pharma focused on narcolepsy, oncology, pain, and psychiatry. Shares in the company are up about 125% over the past year, so it must be doing something right.

Watch the following video to see whether senior biotech specialist Brian Orelli and health-care analyst David Williamson give the companies a goal, raise a yellow card, or send them off with a red card.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The article Of These 3 Battleground Biotech Stocks, 1 Is a Buy originally appeared on Fool.com.

Brian Orelli has no position in any of the stocks mentioned. David Williamson owns shares of Amarin. The Motley Fool recommends BMW and Nike and owns shares of Nike. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story